The impact of IDH mutations on AML prognosis remains somewhat controversial, although a generally inferior outcome is seen with IDH1 mutations and a relatively favorable prognosis may be seen with IDH2 mutations, particularly R172K IDH2 mutations, in the setting of standard intensive chemotherapy10–17. This evidence concerns the gene IDH2 and acute myeloid leukemia.